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Human airway trypsin-like protease (HAT), a novel serine protease in the airways, enhances cell growth and IL-8
production. The expression and role of HAT in the skin however, is unknown. Immunoﬂuorescence staining and
reverse transcription (RT)-PCR were done to know HAT production in normal and psoriatic tissues and keratinocyte
cell lines. Cell growth and/or IL-8 release analyses were made by bromo-deoxyuridine (BrdU) uptake and ELISA.
Psoriatic epidermis showed more extensive immunoﬂuorescence expression of HAT, and less extensive
expression of protease-activated receptor (PAR)-2. RT-PCR demonstrated a higher HAT and a lesser PAR-2 mRNA
expressions in psoriatic epidermis. Normal keratinocyte and epidermoid carcinoma cell lines expressed HAT and
PAR-2 mRNA, and immortalized keratinocytes (HaCaT) expressed PAR-2, but not HAT mRNA. PAR-2 was detected
along the keratinocyte surface in culture and became invisible upon HAT stimulation, suggesting a process of its
internalization. HAT or PAR-2 activating peptide did not enhance BrdU uptake, but induced an IL-8 release.
Treatment with HAT and IL-1b synergistically increased the effect of IL-8 release. Inhibition of PAR-2 resulted in a
decreased HAT-induced IL-8 release. Thus, HAT might promote PAR-2-mediated IL-8 production to accumulate
inﬂammatory cells in the epidermal layer of psoriasis.
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A novel serine protease, human airway trypsin-like protease
(HAT) was isolated from mucoid sputa of the patients with
chronic airway diseases (Yasuoka et al, 1997). HAT cDNA
was cloned and the amino acid sequence was deduced by
Yamaoka et al (1998). This monometric 27 kDa trypsin-like
protease consisted of a 232-residue catalytic region and a
186-residue non-catalytic region with a hydrophobic puta-
tive transmembrane domain near the NH2 terminus. HAT is
synthesized in a precursor form and develops into an active
protease by partial proteolytic cleavage of the molecule,
although the detailed mechanism is so far unknown. HAT is
localized in the airway epithelial cells (Takahashi et al, 2001)
and its mRNA is detectable predominantly in the trachea
(Yamaoka et al, 1998). The biological function of HAT has
been under extensive investigations, demonstrating such
functions as degradation of serum fibrinogen or airway
mucus (Yoshinaga et al, 1998), proliferation of lung
fibroblasts (Miki et al, 2001), interleukin (IL)-8 release from
bronchial epithelial cells (Miki et al, 2002).
Protease-activated receptors (PARs), including PAR-1,
PAR-2, PAR-3, and PAR-4 comprise, members of a seven
transmembrane G-protein coupled receptor family (Dery
et al, 1998; Macfarlane et al, 2001). They are widely
distributed in a large variety of cells in the body, including
PAR-1 and PAR-2 in keratinocytes (Santulli et al, 1995;
Derian et al, 1997, D’Andrea et al, 1998), and participate in
inflammation and cell growth. Partially cleaved with serine
proteases such as thrombin and trypsin, at the extracellular
N-terminus, PARs expose a tethered ligand domain, which
binds the second extracellular loop of the receptors to elicit
themselves. Signals are transmitted to the nucleus to
participate in various functions. PAR’s activating peptides
(agonist) correspond to the sequence of tethered ligand are
known to carry out the functions without serine proteases.
In this regard, Miki et al (2002) clearly demonstrated that
HAT-induced IL-8 release in human bronchial epithelial cells
in a concentration-dependant manner. They (Miki et al,
2003) also showed an intracellular calcium increase in a
biphasic manner, which is an identical reaction demon-
strated by the PAR-2 activation induced by the PAR-2
agonist peptide. Moreover, they clearly demonstrated a
desensitization response of calcium flux when HAT was
applied to human bronchial epithelial cells, which were
under PAR-2 agonist peptide stimulation. This is consistent
with the desensitization reaction of PAR-2 induced by
trypsin as previously described by Bohm et al (1996).
Together, HAT might play a role like trypsin via the surface
PAR-2 leading to elicitation of human bronchial epithelial
cells. Despite of these physiologic evidences in lung cells,
Abbreviations: BrdU, bromo-deoxyuridine; HAT, human airway
trypsin-like protease; IL-8, interleukin-8; NHEK, normal human
epidermal keratinocyte; PAR, protease-activated receptor
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the basic knowledge on HAT as related to the skin remains
to be elucidated.
Psoriasis vulgaris is a chronic, disfiguring skin lesion
characterized by epidermal proliferation and a loss of
keratinocyte differentiation, and inflammatory cell infiltrates
to form intraepidermal microabscess (Camp, 1998). An
essential role of T cells has been notified as the pathogen-
esis of this disease (Barker, 1991; Nickoloff and Wrone-
Smith, 1999). Subsequently, IL-8 has been found in much
higher levels in keratinocytes from psoriatic lesions (Gius-
tizieri et al, 2001). These cellular and tissue reactions in
psoriatic skin led us to examine putative functions of HAT in
the skin disease.
In order to know whether HAT, though originally found in
the airways, might be expressed in the normal and psoriatic
skins, and whether it might mediate any particular biological
function, we examined the effect of HAT on cell growth and
IL-8 production in epidermal keratinocytes in normal and
psoriatic skins and normal keratinocyte and epidermoid
carcinoma cell lines, using immunofluorescence, ELISA,
bromo-deoxyuridine (BrdU)-uptake and RT-PCR methods.
Here, we demonstrate for the first time that HAT is
biosynthesized in the skin, and epidermal keratinocytes are
responsible for IL-8 release possibly via the pathway
involving PAR-2 activation. Thus, HAT may play a critical
role to induce intraepidermal microabscess formation in
psoriasis vulgaris, which in turn provide clues for developing
new treatments for psoriatic lesions.
Results
Distribution of HAT, PAR-2, and IL-8 in skin biopsy
tissues HAT was demonstrated in a diffuse homogeneous
pattern in the cytoplasm of keratinocytes through the whole
epidermal layers in both normal and psoriatic skins (Fig 1A,
C). Negative control normal skin reacted with normal mouse
IgG showed no specific immunofluorescence staining (Fig
1B). The immunofluorescence staining of HAT in psoriatic
epidermis appeared more extensive and intense than that in
the normal skin. The suprabasal layer of psoriatic skin
tended to show a more intense reaction for HAT (Fig 1C),
and negative control section stained with normal mouse
IgG showed no reaction in the psoriatic epidermis (Fig 1D).
The cytoplasm of epidermal keratinocytes in both normal
and psoriatic skins was diffusely positive for PAR-2, but
the fluorescence intensity was significantly diminished in
the psoriatic epidermis (Fig 1E, F). Compared to the
normal epidermis (Fig 1G), IL-8 fluorescence positive cells
were highly extensive and densely populated in psoriasis
(Fig 1H). Trypsin was not retrieved by immunofluorescence
technique in both normal and psoriatic skins (figures not
shown).
Expression of HAT and PAR-2 mRNA in normal and
psoriatic epidermal keratinocytes The expression of HAT
mRNA was significantly higher in psoriatic lesions than
in the normal counterparts (po0.001) (Fig 2A). On the
contrary, the expression of PAR-2 mRNA in psoriatic
epidermis was significantly lower than in the normal control
(po0.05) (Fig 2B). The expression of trypsin mRNA was not
detectable either in the normal or psoriatic epidermis (data
not shown).
Expression of HAT and PAR-2 mRNA in cells of various
cell lines RT-PCR analyses demonstrated the expression
Figure1
Distribution of HAT, PAR-2, and IL-8 in normal and psoriatic skin.
The cytoplasm of normal keratinocytes was reactive for HAT through
the epidermal layer (A), and control section showed negative staining
with negligible granular fluorescence at the uppermost cornified layer of
normal skin (B). Psoriatic epidermis showed more diffuse and extensive
reaction for HAT, especially at suprabasal layer (C), and no reaction was
seen in the psoriatic epidermis when normal mouse IgG was applied
instead of the primary antibody (D). The intensity of PAR-2 immunos-
taining in the normal skin (E) was distinct as compared to diminished
reaction in psoriatic skin (F). Compared to the normal epidermis (G), IL-
8 fluorescence positive cells were highly extensive and densely
populated in psoriasis (H). Scale bar¼ 20 mm.
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of HAT mRNA at clearly detectable levels in A431 cells and
normal human keratinocytes of adults and neonates, but
traces in HaCaT cells (Fig 3A). Expression of PAR-2 mRNA
was readily detectable in each of the normal and cancer cell
lines (Fig 3B).
Effect of HAT on DNA synthesis and cell growth BrdU
incorporation assay in HaCaT cells showed a gradual
decrease by HAT treatment in a concentration-dependent
manner, which was significant at 200mU per mL (po0.05)
(Fig 4A). Treatment of HaCaT cells with SLIGKV-
NH2 showed no remarkable influence on DNA synthesis
(Fig 4B). Cell growth assay indicated that neither HAT nor
SLIGKV-NH2 showed significant influences on the cell
proliferation in HaCaT cells (Fig 4C, D).
Effects of HAT on PAR-2 internalization and its recruit-
ment Before HaCaT cells were exposed to HAT (0 min),
PAR-2 appeared to be localized along the cell surface and
at perinuclear envelope in the cells (Fig 5A; arrows), and
a small number of reactive granules were found in the
cytoplasm (Fig 5A; arrowhead). After 15 min of HAT
stimulation, the intensity of PAR-2 expression in the cells
significantly diminished (Fig 5B). Then, dense granules
reactive for PAR-2 appeared in the cytoplasm and tended
to increase in number by 30 min stimulation (Fig 5C).
Effect of HAT on the IL-8 production ELISA analyses
demonstrated that the addition of HAT or SLIGKV-NH2
enhanced IL-8 release from HaCaT cells in a concentration-
dependent manner (Fig 6A, B). A synergistic effect in IL-8
release was shown in HaCaT and A431 cells, and normal
adult and neonate keratinocytes when the cells were
stimulated with both HAT and IL-1b. The IL-8 release by
IL-1balone was 10-fold higher than by HAT stimulation alone
in normal adult keratinocytes, and it was about 25-fold
higher when a combined stimulation of HAT and IL-1b
was applied (Fig 7). HaCaT cells treated with anti-PAR-2
antibody resulted in a significant decrease of IL-8 release by
stimulation of either HAT or SLIGKV-NH2 (Fig 8A, B).
Discussion
In this study, we have demonstrated novel findings related
to the expression of HAT in normal and psoriatic epidermal
keratinocytes. Active synthesis of HAT was demonstrated
by RT-PCR analyses in keratinocytes in tissue and in cell
lines. HAT mRNA was highly upregulated in psoriatic
epidermis compared to the normal counterpart. Immuno-
fluorescence intensity of HAT expression appeared much
intensive in the epidermal keratinocytes of psoriasis than
normal skin. Psoriatic epidermal layer was thicker and the
keratinocytes reactive for HAT were widely distributed,
being consistent with a relatively higher expression of HAT
Figure 2
Expression of HAT and PAR-2 mRNA in psoriatic and normal skin
biopsy tissues. Total RNAs from epidermal layers of seven psoriatic
and four normal skin tissues were analyzed by RT-PCR for HAT and
PAR-2 mRNA expression. The intensity of the amplified signals was
normalized against GAPDH mRNA as an internal control. The results
were statistically compared by the Student’s t test. HAT mRNA
expression in psoriatic epidermis (A) was significantly higher than in
normal epidermis (po0.001). In contrast, PAR-2 mRNA in psoriatic
epidermis (B) was lower than normal epidermis (po0.05). Error bar
indicates standard deviation (SD).
Figure3
Expression of HAT and PAR-2 mRNA in cells of various cell lines.
HAT mRNA was clearly expressed in A431, NHEK-Ad and NHEK-Neo
cells, but faintly in HaCaT cells (A). PAR-2 mRNA was expressed in
each of the cell lines (B). Error bar indicates standard deviation (SD).
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mRNA. In contrast, trypsin was not retrieved in the tissues
or culture cells of normal human keratinocytes, epidermoid
carcinoma (A431) cells and HaCaT cells. HAT did not
increase growth activity in keratinocytes, but induced IL-8
release from keratinocytes to a limited extent which was
synergistically increased by the addition of IL-1b. Treatment
of PAR-2 by its own antibody led to a significant decrease of
HAT- and activating peptide-induced IL-8 release from
HaCaT cells.
According to Koshikawa et al (1998), trypsin mRNA was
not found in the normal human skin by northern blotting,
and in situ hybridization method, and only a weak
expression was retrieved in formalin-fixed paraffin sections.
In addition, immunoperoxidase staining showed uneven
scant positive reaction in the basal epidermal cells that
were quite indistinguishable from melanin pigments. In
the present study, the immunofluorescence staining with
the same monoclonal antibody failed to demonstrate a
positive reaction for trypsin in the skin. Trypsin mRNA was
not detected in keratinocytes in tissues and cell lines, either.
These findings suggest that trypsin may exist in an
insignificant amount if any in the keratinocytes. Trypsin (-
ogen) comprised at least four different subtypes and some
other trypsin-like proteases should coexist in cells of many
tissues (Koshikawa et al, 1998). HAT might serve as a
trypsin-like protease in epidermal keratinocytes and elicit
epidermal PAR-2 to undertake biological functions. The
functional similarities between HAT and trypsin were
suggested based on several indirect evidences, including:
(1) HAT stimulation led to an increase of calcium influx in
bronchial epithelial cells similar to that by PAR-2 activating
peptide that was assumed to carry out functions corre-
sponding to trypsin (Miki et al, 2003), (2) leupepsin and
aprotinin, serine protease inhibitors, suppressed PAR-2
activation by HAT as much as by trypsin, and (3) denatura-
tion of HAT by boiling inhibited its enhancing effect on a
protease (Chokki et al, 2003, in press).
Previous studies suggested that mast cell tryptase
played a role to activate PAR-2, e.g., in human lung
fibroblast (Akers et al, 2000). Indeed, mast cells have been
observed in increased number in lesional psoriatic skin, and
tryptase positive mast cells were increased in number in the
upper dermis of the lesion (Harvima et al, 1999). On the
other hand, Yasuoka et al (1996) compared HAT with mast
cell tryptase in the response to several protease inhibitors.
They indicated that mast cell tryptase was inhibited by
about 80% by secretory leukocyte protease inhibitor, main
protease inhibitor produced by mucosal surface cells in the
airways. But HAT was little inhibited by secretory leukocyte
protease inhibitor. In contrast, HAT was inhibited by a1-
protease inhibitor, which was main protease inhibitor in
serum by about 50%. However, mast cell tryptase was not
Figure 4
Measurement of BrdU incorporation and cell proliferation after
treatment with HATor PAR-2 activating peptide. DNA synthesis was
assessed with BrdU incorporation by HaCaT cells after treatment with
HAT (A) or PAR-2 activating peptide; SLIGKV-NH2 (B). HAT showed a
rather inhibitory effect on DNA synthesis in a concentration-dependent
manner (A). The activating peptide did not show any significant
influence (B). Results are expressed as fold increase against the non-
treated samples. po0.05 Cell number was counted after treatment
with HAT or SLIGKV-NH2. Neither HAT (C) nor SLIGKV-NH2 (D) showed
any remarkable influence on the proliferating activity of HaCaT cells.
The data shown are mean  SD.
Figure 5
Localization of PAR-2 in HaCaT cells after exposure to HAT. HaCaT cells were incubated with HAT for 0, 15, or 30 min, then immediately fixed.
Before exposure to HAT (A), PAR-2 was expressed along the nuclear envelope and cell surfaces (arrows). Few dense granules (arrowhead) were
scattered in the cytoplasm. Following 15 min exposure to HAT (B), the intensity of PAR-2 diminished to a large extent. At 30 min exposure (C), a
number of dense granules (arrowheads) reappeared in the cytoplasm. Scale bar¼ 20 mm.
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inhibited. Wingens et al (1998) reported that secretory
leukocyte protease inhibitor was expressed at low levels in
normal skin and it was clearly upregulated in psoriatic skin.
So, we considered that the function of HATexceeded that of
mast cell tryptase especially in psoriatic epidermis.
HAT exerts cell growth activity with an increased DNA
synthesis in lung fibroblasts (Miki et al, 2001). In our study,
treatment of HaCaT cells with HAT did not show an
increased growth activity, but rather inhibited DNA uptake
in a concentration-dependent manner. This is in accord with
the finding by Derian et al (1997) who demonstrated an
inhibitory role of PAR-2 activating peptide on the cell
growth. Thus, HAT may not contribute to the proliferation
of keratinocytes in psoriatic epidermis.
With regard to interleukin release, HAT induced a
relatively small amount of IL-8 release from all the cell lines
examined in this study. The release of IL-8 by HAT was
synergistically increased by combined treatment with IL-1b
(about 25-fold more than HAT alone, and 2.7-fold than more
than IL-1balone in normal adult keratinocytes). This is in
agreement with the pathologic function of HAT in chronic
airway diseases in which a large number of neutrophilic
leukocytes are accumulated in bronchial epithelial layers.
Bronchial epithelial cells are the primary origin of HAT and
consistently exposed to proinflammatory cytokines such as
IL-1b in airway disease (Yasuoka et al, 1997). Moreover,
psoriatic plaques contain massive infiltration of inflamma-
tory cells such as neutrophils and T lymphocytes (Prinz et al,
1994). Inflammatory cytokines, including IL-1a, IL-1b
(Debets et al, 1995), IL-6 (Ohta et al, 1991), and IL-8 (Hou
et al, 1998) have been widely implicated as etiologic factors
to induce the characteristic feature of psoriasis, such as
intraepidermal abscess. A higher expression of IL-8 shown
by Gillitzer et al (1991) and Nickoloff et al (1994) represented
a local characterization of the psoriatic lesion. We also
found the higher expression of IL-8 in psoriatic than normal
epidermis in the present study. Therefore, the extensive
expression of HAT in psoriatic keratinocytes might result in
profound infiltration of inflammatory cells mediated by IL-8
release that might be synergistically effected by IL-1b.
In the present study, the cell surface receptor, PAR-2 was
expressed less intensely in psoriatic epidermis compared
to the normal counterpart. Consistent with this, Hou et al
(1998) also demonstrated reduced intensity of PAR-2
staining in suprabasal layers of psoriatic epidermis. Steinh-
off et al (1999) showed that hyperproliferative squamous
keratinocytes expressed PAR-2 weakly compared to a
strong expression at the granular layer of the normal skin.
Reduction of PAR-2 staining intensity might be related to
some biological functions, including perhaps interactions
with HAT expression in epidermal keratinocytes.
In our study, immunofluorescence expression of PAR-2 in
keratinocytes was lost following the treatment with HAT, and
then reappeared in the cytoplasm of keratinocytes. The loss
of expression of PAR-2 was attributed to its internalization
Figure 6
Increased IL-8 production after treatment with HAT or PAR-2
activating peptide. After 48 h treatment with HAT (0–200 mU per mL)
(A) or SLIGKV-NH2 (0–800 mM) (B), IL-8 release from HaCaT cells was
increased in a concentration-dependent manner. The data shown are
mean  SD. po0.05, po0.001.
Figure 7
Effect on IL-8 release by treatment with HAT, IL-1b, or their
combination. Following 24 h treatment with HAT (100 mU per mL) or
IL-1b(100 ng per mL), IL-8 release was induced in HaCaT, A431, NHEK-
Ad, or NHEK-Neo cells. Combined treatment of HAT and IL-
1bsynergistically enhanced IL-8 production in each cell line. The data
shown are mean  SD.
Figure8
Inhibition of IL-8 release by the treatment with anti-PAR-2
antibody. IL-8 release from HaCaT cells decreased by the treatment
with anti-PAR-2 antibody (0.02, 0.2, 2 mg per mL) combined with either
HAT (20 mU per mL) (A), or SLIGKV-NH2 (400 mM) (B). The data shown
are mean  SD. po0.05.
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suggesting its activation as previously described by Bohm
et al (1996) and Hollenberg and Compton (2002). It is known
that repeated activations of PAR-2 by trypsin lead to
desensitization of the Ca2þ response in cells. In this
process the surface receptor, PAR, is internalized for
lysosomal degradation in the cytoplasm. New synthesis of
PAR takes place in Golgi complex and the receptor is
relocated to the cell surfaces in due time. A lesser
expression of PAR-2 in psoriatic epidermis notified in the
present study might be related to recurrent interactions
between HAT and PAR-2.
HaCaT cells treated with anti-PAR-2 antibody resulted in
a significant decrease of IL-8 release under stimulation of
HAT. This reaction implies that HAT-induced IL-8 release is
closely dependent on PAR-2 activation. And a similar
inhibitory reaction by the antibody under stimulation of
activating peptide of PAR-2 gives a further support for the
mediation of PAR-2 in HAT-induced reactivity.
We conclude that HAT might promote PAR-2-mediated
IL-8 production to accumulate neutrophils in the epidermal
layer of psoriasis vulgaris, and intervention with excess HAT
activity may provide new clues for the treatment of this
disease.
Materials and Methods
Tissue specimens Biopsy skin tissues were obtained from seven
patients with psoriasis vulgaris (six males and one female) with a
mean age of 54.6 y (range: 23–78 y) who had typical clinical
symptoms. The tissues were divided into two groups; one group
was fixed in 10% buffered formalin for paraffin embedding, and the
other was not fixed for immunofluorescence study and RT-PCR
analysis. The histopathologic diagnosis was confirmed as typical
psoriasis vulgaris characterized by hyperkeratosis, acanthosis, and
microabscess formation in upper epidermis. Normal skin biopsies
were taken from fourage-matched normal adult volunteers (three
males and one female). All biopsies were taken after obtaining
informed consents from the patients, and this study was approved
by the institutional review board of the Nippon Medical School.
Cell cultures Normal human epidermal keratinocytes derived
from adult breast skin (NHEK-Ad) and neonatal foreskin (NHEK-
Neo) were obtained from Clonetics (San Diego, California) and
cultured in serum-free keratinocyte growth medium (KGM-2,
Clonetics). They were used at two to three passages for the
experiments. The spontaneously immortalized human keratinocyte
cell line (HaCaT) (Boukamp et al, 1988) was kindly provided by Dr
N.E. Fusenig (DKFZ, Heidelberg, Germany). The human epider-
moid carcinoma cell line (A431) was purchased from the Riken Cell
Bank (Ibaraki, Japan). HaCaT and A431 cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma, St Louis,
Missouri) supplemented with 10% FBS and antibiotics. Cells were
incubated at 371C in a 5% CO2 incubator.
Reagents Recombinant HAT was a kind gift from Teijin Institute for
Bio-Medical Research, Tokyo, Japan. It was prepared as
described recently (Miki et al, 2003). Human recombinant IL-1b
was purchased from R&D systems (Minneapolis, Minnesota), and
PAR-2 activating peptide (SLIGKV-NH2) was from Bachem
(Bubendorf, Switzerland).
Immunoﬂuorescence study Skin biopsy tissues were embedded
in OCT compound without fixation, snap frozen in liquid nitrogen
and stored at 801C until sectioning. An indirect immunofluores-
cence method was applied to frozen sections of 4 mm thickness.
The sections were acetone-fixed for 10 min and treated with 10%
normal horse serum or normal goat serum for 20 min, then
incubated 3 d at 41C with 1:200 dilution of mouse monoclonal
antibody against HAT (Takahashi et al, 2001), overnight with 1:400
dilution of rabbit polyclonal antibody against PAR-2, 1:150 dilution
of mouse monoclonal antibody against human pancreatic trypsin
(Chemicon, Temecula, California) or 1:100 dilution of mouse
monoclonal antibody against IL-8 (Pepro Tech EC, London, UK)
as primary antibodies. Anti-HAT and PAR-2 antibodies were kind
gifts from Teijin Institute for Bio-Medical Research, Tokyo, Japan.
After washing several times with phosphate-buffered saline, the
sections were incubated with secondary antibodies consisting of
1:100 dilution of FITC-labeled horse anti-mouse (for anti-HAT,
trypsin or IL-8 antibodies) or goat anti-rabbit (for anti-PAR-2
antibody) IgGs (Vector Laboratories, Burlingame, California) for 60
min at room temperature in the dark. Nuclear counterstaining was
done for 15 min at room temperature with 0.01% TOTO-3 iodide
(Molecular Probes, Eugene, Oregon). The sections were examined
with a confocal laser scanning microscope (Model TC-SP, Leica,
Heidelberg, Germany) equipped with argon and argon-krypton
laser sources (Jin et al, 2003). In the results, green fluorescence
represented HAT, PAR-2, or IL-8, and blue fluorescence depicted
the cellular nuclei.
As control, normal mouse IgG was applied instead of antibody
to HAT, trypsin, or IL-8, and normal rabbit IgG instead of antibody
to PAR-2 in the immunostaining method.
To investigate whether surface PAR-2 was elicited in epidermal
cells, we examined intracellular mobilization of the PAR-2 receptor
protein following the HAT stimulation. HaCaT cells were cultured in
chamber glass slides (Nalge Nunc, Rochester, New York) with
complete medium for 24h. After incubation for 24 h in serum-free
medium, the cells were treated with HAT (100 mU per mL). Cells at
0, 15, and 30 min after treatment were fixed with acetone for 20
min. An indirect immunofluorescence method was applied with
PAR-2 antibody as described, and the images were obtained
through a full thickness of cells without nuclear staining.
RNA preparation, cDNA synthesis, and RT-PCR analysis Epi-
dermal layer of the normal and psoriatic skin tissues was separated
with a razor blade under a stereoscope. Total RNA was extracted
from epidermal or cultured keratinocytes using the RNeasy Mini Kit
(Qiagen, Hilden, Germany). Complementary DNA (cDNA) was
synthesized from 240 ng (epidermal keratinocytes) and 1 mg
(culture cells) of total RNA with oligo (dT) using SuperScript II
RNase H Reverse Transcriptase (Gibco BRL, Rockville, Mary-
land). RT-PCR was carried out for HAT, trypsin, PAR-2, and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) using Ex-
pand High Fidelity PCR System (Roche, Mannheim, Germany)
according to the manufacturer’s instruction. GAPDH was used as
an internal control. Dilution of RT products was based on the log-
linear relationship between the cDNA and the signal intensity of the
GAPDH PCR products. RT-PCR was performed (Jin et al, 2003)
using the following oligonucleotides as primers: HAT (a kind gift
from Teijin Institute for Bio-Medical Research) forward 50-
CATTGTCGTCGCAGGGGTAG-30 (nucleotides 124–143), reverse
50-TCAGCCTCAGTGCCTCCAAG-30 (nucleotides 623–642), trypsin
(Koshikawa et al, 1997) forward 50-ACGAATTCACAAGTCCCG-
CATCCAG-30 (nucleotides 200–216), reverse 50-ACGAATTCCCAC-
CAGAATCACCCTG-30 (nucleotides 595–611), and PAR-2 (a kind
gift from Teijin Institute for Bio-Medical Research) forward 50-
TGGATGAGTTTTCTGCATCTGTCC-30(nucleotides 329–352), re-
verse 50-CGTGATGTTCAGGGCAGGAATG-30 (nucleotides 798–
819). The expected PCR products were 519, 412, and 491 bp for
HAT, trypsin, and PAR-2, respectively. PCR was performed for HAT
by denaturation at 941C for 30 s, annealing at 601C for 1 min, and
extension at 721C for 1 min for 35 cycles, for PAR-2 by
denaturation at 941C for 45 s, annealing at 581C for 45 s, and
extension at 721C for 2 min for 30 cycles, and for trypsin by
denaturation at 941C for 1min, annealing at 541C for 1min, and
extension at 721C for 2 min for 35 cycles. The PCR products were
electrophoresed on 2% agarose gels and visualized by ethidium
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bromide staining. Semiquantitative measurement of each mRNA
was done using Molecular Imager FX and Quantity One Software
Package (Bio Rad Laboratories, Hercules, California).
Measurement of BrdU incorporation To investigate whether HAT
induces DNA-synthesis or cell growth in keratinocytes, HaCaT cells
were seeded in 96-well plates at a density of 3  103 cells per well
and cultured in DMEM with 10% FBS. After reaching subcon-
fluence, the cells were incubated in serum-free DMEM for 48h. HAT
(0, 2, 20, 200 mU per mL) or PAR-2 activating peptide (SLIGKV-
NH2) (0, 1, 10, 100, 500 mM) was added for 24 h. BrdU was added
to the medium for the last 18 h of incubation. Incorporation of BrdU
was determined using the BrdU Labeling Detection kit (Boehringer
Mannheim, Mannheim, Germany) according to the manufacturer’s
instructions. The absorbance was measured at 405 nm. Experi-
ments were done three times. In addition, the cell number was
counted before and after the incubation of HaCaT cells with HAT
and SLIGKV-NH2, respectively. HaCaT cells were seeded in 12-well
plates at a density of 1.5  105 cells per well and cultured in
DMEM with 10% FBS. After reaching subconfluence, the medium
was replaced with serum-free DMEM for 48 h, and HAT or SLIGKV-
NH2 was added. The cell number was counted 24 h later.
ELISA for IL-8 To investigate the effect of HATon the release of IL-
8 from keratinocytes, IL-8 in the culture media of A431 and HaCaT
cells, and normal keratinocytes (NHEK-Ad and NHEK-Neo cells)
was measured by ELISA after incubation with HAT (100 mU per
mL). The same experiments were carried out with IL-1b (100 ng per
mL) treatment which is known to enhance IL-8 release in various
kinds of cells. In addition, a combination of HAT and IL-1bwas also
tested to investigate its effect on IL-8 release. Cells were seeded in
24-well plates at 5  104 cells per well and cultured until
confluence. The cells were harvested in serum- or supplement-
free medium for 24 h before stimulation with HAT, IL-1b or their
combination. Cells were harvested at 24 and 48 h after the
treatments, and the IL-8 production in the culture media was
measured by ELISA (R&D systems, Minneapolis, Minnesota). To
examine effects of HAT and the activating peptide on PAR-2
induced IL-8 production in HaCaT cells, the cells were stimulated
with HAT (0–200mU per mL) or SLIGKV-NH2 (0–800 mM) and
harvested for 48h. The supernatants were examined for IL-8
production by ELISA.
To evaluate whether PAR-2, being activated by partial proteo-
lytic cleavage with HAT, might mediate IL-8 release, we examined
the inhibitory effect of anti-PAR-2 antibody in neutralizing the HAT-
induced IL-8 production. HaCaT cells were prepared as described
above. They were pre-incubated with anti-PAR-2 antibody (0.02,
0.2, 2 mg per mL) for 1h. Then cells were stimulated with anti-PAR-2
antibody combined with either HAT (20mU per mL), or SLIGKV-NH2
(400 mM). Cells were harvested at 24 h and IL-8 production in
culture media was measured by ELISA.
Statistics The Bonferroni/Dunn test and the unpaired Student’s t
test were used for statistical comparison. p-Value of less than 0.05
was considered as significant. All values were given as mean  SD.
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